Literature DB >> 26129791

The NASH drug dash.

Kelly Rae Chi.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 26129791     DOI： 10.1038/nrd4667

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  5 in total

1.  Hippo-mediated suppression of IRS2/AKT signaling prevents hepatic steatosis and liver cancer.

Authors:  Sun-Hye Jeong; Han-Byul Kim; Min-Chul Kim; Ji-Min Lee; Jae Ho Lee; Jeong-Hwan Kim; Jin-Woo Kim; Woong-Yang Park; Seon-Young Kim; Jae Bum Kim; Haeryoung Kim; Jin-Man Kim; Hueng-Sik Choi; Dae-Sik Lim
Journal:  J Clin Invest       Date:  2018-02-05       Impact factor: 14.808

2.  Human hepatic in vitro models reveal distinct anti-NASH potencies of PPAR agonists.

Authors:  Tamara Vanhaecke; Robim M Rodrigues; Joost Boeckmans; Alessandra Natale; Matthias Rombaut; Karolien Buyl; Brent Cami; Veerle De Boe; Anja Heymans; Vera Rogiers; Joery De Kock
Journal:  Cell Biol Toxicol       Date:  2020-07-01       Impact factor: 6.691

3.  Salidroside Modulates Insulin Signaling in a Rat Model of Nonalcoholic Steatohepatitis.

Authors:  Hongshan Li; Hao Ying; Airong Hu; Dezhou Li; Yaoren Hu
Journal:  Evid Based Complement Alternat Med       Date:  2017-02-01       Impact factor: 2.629

4.  The Combination of Blueberry Juice and Probiotics Ameliorate Non-Alcoholic Steatohepatitis (NASH) by Affecting SREBP-1c/PNPLA-3 Pathway via PPAR-α.

Authors:  Tingting Ren; Juanjuan Zhu; Lili Zhu; Mingliang Cheng
Journal:  Nutrients       Date:  2017-02-27       Impact factor: 5.717

Review 5.  KDM6 Demethylases and Their Roles in Human Cancers.

Authors:  Chunyan Hua; Jiaqing Chen; Shuting Li; Jianan Zhou; Jiahong Fu; Weijian Sun; Wenqian Wang
Journal:  Front Oncol       Date:  2021-12-07       Impact factor: 6.244
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.